175 related articles for article (PubMed ID: 29410730)
21. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
22. Protein kinase Cα mediates erlotinib resistance in lung cancer cells.
Abera MB; Kazanietz MG
Mol Pharmacol; 2015 May; 87(5):832-41. PubMed ID: 25724832
[TBL] [Abstract][Full Text] [Related]
23. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.
Yamasaki F; Johansen MJ; Zhang D; Krishnamurthy S; Felix E; Bartholomeusz C; Aguilar RJ; Kurisu K; Mills GB; Hortobagyi GN; Ueno NT
Cancer Res; 2007 Jun; 67(12):5779-88. PubMed ID: 17575145
[TBL] [Abstract][Full Text] [Related]
24. Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.
Dai B; Yan S; Lara-Guerra H; Kawashima H; Sakai R; Jayachandran G; Majidi M; Mehran R; Wang J; Bekele BN; Baladandayuthapani V; Yoo SY; Wang Y; Ying J; Meng F; Ji L; Roth JA
PLoS One; 2015; 10(6):e0123967. PubMed ID: 26053020
[TBL] [Abstract][Full Text] [Related]
25. Nrf2-driven TERT regulates pentose phosphate pathway in glioblastoma.
Ahmad F; Dixit D; Sharma V; Kumar A; Joshi SD; Sarkar C; Sen E
Cell Death Dis; 2016 May; 7(5):e2213. PubMed ID: 27148686
[TBL] [Abstract][Full Text] [Related]
26. Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-alpha.
Yang JL; Qu XJ; Hayes VM; Brenner PC; Russell PJ; Goldstein D
BJU Int; 2007 Jun; 99(6):1539-45. PubMed ID: 17346275
[TBL] [Abstract][Full Text] [Related]
27. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
[TBL] [Abstract][Full Text] [Related]
28. Correlation of HER1/EGFR expression and degree of radiosensitizing effect of the HER1/EGFR-tyrosine kinase inhibitor erlotinib.
Kim JC; Ali MA; Nandi A; Mukhopadhyay P; Choy H; Cao C; Saha D
Indian J Biochem Biophys; 2005 Dec; 42(6):358-65. PubMed ID: 16955736
[TBL] [Abstract][Full Text] [Related]
29. The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor.
Bolitho C; Hahn MA; Baxter RC; Marsh DJ
Endocr Relat Cancer; 2010 Dec; 17(4):929-40. PubMed ID: 20702723
[TBL] [Abstract][Full Text] [Related]
30. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
[TBL] [Abstract][Full Text] [Related]
31. Drug resistance associates with activation of Nrf2 in MCF-7/DOX cells, and wogonin reverses it by down-regulating Nrf2-mediated cellular defense response.
Zhong Y; Zhang F; Sun Z; Zhou W; Li ZY; You QD; Guo QL; Hu R
Mol Carcinog; 2013 Oct; 52(10):824-34. PubMed ID: 22593043
[TBL] [Abstract][Full Text] [Related]
32. PM2.5 induces Nrf2-mediated defense mechanisms against oxidative stress by activating PIK3/AKT signaling pathway in human lung alveolar epithelial A549 cells.
Deng X; Rui W; Zhang F; Ding W
Cell Biol Toxicol; 2013 Jun; 29(3):143-57. PubMed ID: 23525690
[TBL] [Abstract][Full Text] [Related]
33. Quantitative analysis of NRF2 pathway reveals key elements of the regulatory circuits underlying antioxidant response and proliferation of ovarian cancer cells.
Khalil HS; Goltsov A; Langdon SP; Harrison DJ; Bown J; Deeni Y
J Biotechnol; 2015 May; 202():12-30. PubMed ID: 25449014
[TBL] [Abstract][Full Text] [Related]
34. Differential response of DU145 and PC3 prostate cancer cells to ionizing radiation: role of reactive oxygen species, GSH and Nrf2 in radiosensitivity.
Jayakumar S; Kunwar A; Sandur SK; Pandey BN; Chaubey RC
Biochim Biophys Acta; 2014 Jan; 1840(1):485-94. PubMed ID: 24121106
[TBL] [Abstract][Full Text] [Related]
35. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
36. Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
Li S; Liu Z; Zhu F; Fan X; Wu X; Zhao H; Jiang L
Oncol Res; 2013; 21(3):137-44. PubMed ID: 24512728
[TBL] [Abstract][Full Text] [Related]
37. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.
Deng J; Shimamura T; Perera S; Carlson NE; Cai D; Shapiro GI; Wong KK; Letai A
Cancer Res; 2007 Dec; 67(24):11867-75. PubMed ID: 18089817
[TBL] [Abstract][Full Text] [Related]
38. Diosmetin induces apoptosis in ovarian cancer cells by activating reactive oxygen species and inhibiting the Nrf2 pathway.
Zhao F; Hong X; Li D; Wei Z; Ci X; Zhang S
Med Oncol; 2021 Apr; 38(5):54. PubMed ID: 33811596
[TBL] [Abstract][Full Text] [Related]
39. Up-regulation of YPEL1 and YPEL5 and down-regulation of ITGA2 in erlotinib-treated EGFR-mutant non-small cell lung cancer: A bioinformatic analysis.
Wu X
Gene; 2018 Feb; 643():74-82. PubMed ID: 29221754
[TBL] [Abstract][Full Text] [Related]
40. Implications of EGFR inhibition in ovarian cancer cell proliferation.
Bull Phelps SL; Schorge JO; Peyton MJ; Shigematsu H; Xiang LL; Miller DS; Lea JS
Gynecol Oncol; 2008 Jun; 109(3):411-7. PubMed ID: 18423824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]